Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D

Translational Research

Volumn 150, Issue 3, 2007, Pages 153-157

  Deeg, Mark A ^a,b   Raikwar, Nandita S ^a   Johnson, Cynthia ^a   Williams, Craig D ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE D; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MESSENGER RNA; METFORMIN; MULTIVITAMIN; OMEGA 3 FATTY ACID; PHOSPHOLIPASE D; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34548129298     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.03.008     Document Type: Article

References (24)

1. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
2. Amarenco P., Lavallee P., and Touboul P.J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3 (2004) 271-278
3. Hoener M.C., and Brodbeck U. Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins. Eur J. Biochem. 206 (1992) 747-757
4. Deeg M.A., Bierman E.L., and Cheung M.C. GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. J Lipid Res 42 (2001) 442-451
5. Kurtz T.A., Fineberg N.S., Considine R.V., and Deeg M.A. Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D. Metabolism 53 (2004) 138-139
6. Rhode H., Lopatta E., Schulze M., Pascual C., Schulze H.P., Schubert K., et al. Glycosylphosphatidylinositol-specific phospholipase D in blood serum: is the liver the only source of the enzyme?. Clin Chim Acta 281 (1999) 127-145
7. Deeg M.A., Bowen R.F., Williams M.D., Olson L.K., Kirk E.A., and LeBoeuf R.C. Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes. Am J Physiol Endocrinol Metab 281 (2001) E147-E154
8. Maguire G.A., and Gossner A. Glycosyl phosphatidyl inositol phospholipase D activity in human serum. An Clin Biochem 32 (1995) 74-78
9. Raymond F.D., Fortunato G., Moss D.W., Castaldo G., Salvatore F., and Impallomeni M. Inositol-specific phospholipase D activity in health and disease. Clin Sci (Colch) 86 (1994) 447-451
10. Schofield J.N., Stephens J.W., Hurel S.J., Bell K.M., deSouza J.B., and Rademacher T.W. Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats. Mol Genet Metab 75 (2002) 154-161
11. Chalasani N., Vuppalanchi R., Raikwar N.S., and Deeg M.A. Glycosylphosphatidylinositol- specific phospholipase d in nonalcoholic fatty liver disease: a preliminary study. J Clin Endocrinol Metab 91 (2006) 2279-2285
12. Low M.G., and Huang K.-S. Factors affecting the ability of glycosylphosphatidylinositol- specific phospholipase D to degrade the membrane anchors of cell surface proteins. Biochem J. 279 (1991) 483-493
13. Stieger S., Diem S., Jakob A., and Brodbeck U. Enzymatic properties of phosphatidylinositol- glycan-specific phospholipase C from rat liver and phosphatidylinositol-glycan-specific phospholipase D from rat serum. Eur J Biochem 197 (1991) 67-73
14. Raikwar N.S., Cho W.K., Bowen R.F., and Deeg M.A. Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 290 (2006) E463-E470
15. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S., et al. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 140 (1999) 5293-5302
16. Forster L.F., Stewart G., Bedford D., Stewart J.P., Rogers E., Shepherd J., et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164 (2002) 129-145
17. Watts G.F., Chan D.C., Barrett P.H., O'Neill F.H., and Thompson G.R. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 27 (2003) 862-865
18. Asztalos B.F., and Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91 (2003) 12E-17E
19. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43 (2002) 1701-1707
20. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164 (2002) 361-369
21. Shao B., Oda M.N., Vaisar T., Oram J.F., and Heinecke J.W. Pathways for oxidation of high- density lipoprotein in human cardiovascular disease. Curr Opin Mol Ther 8 (2006) 198-205
22. Shao B., Oda M.N., Bergt C., Fu X., Green P.S., Brot N., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 281 (2006) 9001-9004
23. O'Brien K.D., Pineda C., Chiu W.S., Bowen R., and Deeg M.A. Glycosylphosphatidylinositol- specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes. Circulation 99 (1999) 2876-2882
24. Huptas S., Geiss H.C., Otto C., and Parhofer K.G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 98 (2006) 66-69